Pacific Biosciences of California, Inc.

NasdaqGS:PACB 주식 보고서

시가총액: US$603.9m

Pacific Biosciences of California 과거 수익 실적

과거 기준 확인 0/6

Pacific Biosciences of California의 수입은 연평균 -40.2%의 비율로 감소해 온 반면, Life Sciences 산업은 수입이 연평균 11.7%의 비율로 증가했습니다. 매출은 연평균 18.7%의 비율로 증가해 왔습니다.

주요 정보

-40.2%

수익 성장률

-30.8%

EPS 성장률

Life Sciences 산업 성장21.5%
매출 성장률18.7%
자기자본 수익률-87.0%
순이익-227.7%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Nov 12

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Nov 07
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Oct 16
Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Sep 20
Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Aug 21

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

Jul 02
Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Jun 08
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Jun 03

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

Apr 25
These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16
It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01
With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18
What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13
Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28
The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06
Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29
Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

수익 및 비용 분석

Pacific Biosciences of California 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NasdaqGS:PACB 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 24173-394179152
30 Jun 24189-400172168
31 Mar 24200-297174182
31 Dec 23201-307170187
30 Sep 23170-309169185
30 Jun 23146-319162185
31 Mar 23134-321161189
31 Dec 22128-314161193
30 Sep 22137-299153193
30 Jun 22140-206148173
31 Mar 22135-175138145
31 Dec 21131-181124113
30 Sep 21122-3710588
30 Jun 21106-779477
31 Mar 2192-598069
31 Dec 2079297364
30 Sep 2080-468461
30 Jun 2083-517159
31 Mar 2090-537559
31 Dec 1991-847560
30 Sep 1982-1156262
30 Jun 1979-1116861
31 Mar 1976-1096462
31 Dec 1879-1036363
30 Sep 1884-935862
30 Jun 1889-905863
31 Mar 1888-935965
31 Dec 1793-925965
30 Sep 1794-905866
30 Jun 1796-865668
31 Mar 1797-795168
31 Dec 1691-744868
30 Sep 16101-574866
30 Jun 1690-374665
31 Mar 1694-314662
31 Dec 1593-324560
30 Sep 1573-494258
30 Jun 1580-604154
31 Mar 1567-674051
31 Dec 1461-663848
30 Sep 1453-643747
30 Jun 1440-763846
31 Mar 1434-773845
31 Dec 1328-793945

양질의 수익: PACB 은(는) 현재 수익성이 없습니다.

이익 마진 증가: PACB 은(는) 현재 수익성이 없습니다.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: PACB 은(는) 수익성이 없으며 지난 5년 동안 연간 40.2% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 PACB 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: PACB 은(는) 수익성이 없어 지난 해 수익 성장을 Life Sciences 업계( -4.7% )와 비교하기 어렵습니다.


자기자본 수익률

높은 ROE: PACB 현재 수익성이 없기 때문에 마이너스 자본 수익률( -87.01% )을 갖습니다.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기